Serum 25-hydoxyvitamin D concentrations in relation to Hashimoto’s thyroiditis: a systematic review, meta-analysis and meta-regression of observational studies

2019 ◽  
Vol 59 (3) ◽  
pp. 859-872 ◽  
Author(s):  
Mario Štefanić ◽  
Stana Tokić
Keyword(s):  
Systematic Review ◽  
Hashimoto’S Thyroiditis ◽  
Observational Studies ◽  
Meta Analysis ◽  
Hashimoto's Thyroiditis ◽  
Meta Regression

scholarly journals Systematic review and meta-analysis of the proportion of non-typhoidal Salmonella cases that develop chronic sequelae

2014 ◽  
Vol 143 (7) ◽  
pp. 1333-1351 ◽  
Author(s):  
J. KEITHLIN ◽  
J. M. SARGEANT ◽  
M. K. THOMAS ◽  
A. FAZIL
Keyword(s):  
Systematic Review ◽  
Haemolytic Uraemic Syndrome ◽  
Observational Studies ◽  
Meta Analysis ◽  
Fisher Syndrome ◽  
Factors Associated ◽  
Inflammatory Bowel ◽  
Meta Regression ◽  
Irritable Bowel ◽  
Chronic Sequelae

SUMMARYThe objective of this systematic review and meta-analysis was to estimate the proportion of cases of non-typhoidal salmonellosis (NTS) that develop chronic sequelae, and to investigate factors associated with heterogeneity. Articles published in English prior to July 2011 were identified by searching PubMed, Agricola, CabDirect, and Food Safety and Technology Abstracts. Observational studies reporting the number of NTS cases that developed reactive arthritis (ReA), Reiter's syndrome (RS), haemolytic uraemic syndrome (HUS), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or Guillain–Barré syndrome (GBS), Miller–Fisher syndrome (MFS) were included. Meta-analysis was performed using random effects and heterogeneity was assessed using the I2 value. Meta-regression was used to explore the influence of study-level variables on heterogeneity. A total of 32 studies were identified; 25 reported on ReA, five reported on RS, seven reported on IBS, two reported on IBD, two reported on GBS, one reported on MFS, and two reported on HUS. There was insufficient data in the literature to calculate a pooled estimate for RS, HUS, IBD, GBS, or MFS. The pooled estimate of the proportion of cases of NTS that developed ReA and IBS had substantive heterogeneity, limiting the applicability of a single estimate. Thus, these estimates should be interpreted with caution and reasons for the high heterogeneity should be further explored.

scholarly journals Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis

Critical Care ◽  
2021 ◽  
Vol 25 (1) ◽  
Author(s):  
Kollengode Ramanathan ◽  
Kiran Shekar ◽  
Ryan Ruiyang Ling ◽  
Ryan P. Barbaro ◽  
Suei Nee Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Extracorporeal Membrane Oxygenation ◽  
Hospital Mortality ◽  
Observational Studies ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Ecmo Support ◽  
Membrane Oxygenation ◽  
Meta Regression ◽  
Venovenous Ecmo

Abstract Background There are several reports of extracorporeal membrane oxygenation (ECMO) use in patients with coronavirus disease 2019 (COVID-19) who develop severe acute respiratory distress syndrome (ARDS). We conducted a systematic review and meta-analysis to guide clinical decision-making and future research. Methods We searched MEDLINE, Embase, Cochrane and Scopus databases from 1 December 2019 to 10 January 2021 for observational studies or randomised clinical trials examining ECMO in adults with COVID-19 ARDS. We performed random-effects meta-analyses and meta-regression, assessed risk of bias using the Joanna Briggs Institute checklist and rated the certainty of evidence using the GRADE approach. Survival outcomes were presented as pooled proportions while continuous outcomes were presented as pooled means, both with corresponding 95% confidence intervals [CIs]. The primary outcome was in-hospital mortality. Secondary outcomes were duration of ECMO therapy and mechanical ventilation, weaning rate from ECMO and complications during ECMO. Results We included twenty-two observational studies with 1896 patients in the meta-analysis. Venovenous ECMO was the predominant mode used (98.6%). The pooled in-hospital mortality in COVID-19 patients (22 studies, 1896 patients) supported with ECMO was 37.1% (95% CI 32.3–42.0%, high certainty). Pooled mortality in the venovenous ECMO group was 35.7% (95% CI 30.7–40.7%, high certainty). Meta-regression found that age and ECMO duration were associated with increased mortality. Duration of ECMO support (18 studies, 1844 patients) was 15.1 days (95% CI 13.4–18.7). Weaning from ECMO (17 studies, 1412 patients) was accomplished in 67.6% (95% CI 50.5–82.7%) of patients. There were a total of 1583 ECMO complications reported (18 studies, 1721 patients) and renal complications were the most common. Conclusion The majority of patients received venovenous ECMO support for COVID-19-related ARDS. In-hospital mortality in patients receiving ECMO support for COVID-19 was 37.1% during the first year of the pandemic, similar to those with non-COVID-19-related ARDS. Increasing age was a risk factor for death. Venovenous ECMO appears to be an effective intervention in selected patients with COVID-19-related ARDS. PROSPERO CRD42020192627.

Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-analysis

Thyroid ◽  
2010 ◽  
Vol 20 (10) ◽  
pp. 1163-1173 ◽  
Author(s):  
Konstantinos A. Toulis ◽  
Athanasios D. Anastasilakis ◽  
Thrasivoulos G. Tzellos ◽  
Dimitrios G. Goulis ◽  
Dimitrios Kouvelas
Keyword(s):  
Systematic Review ◽  
Hashimoto’S Thyroiditis ◽  
Meta Analysis ◽  
Selenium Supplementation ◽  
Hashimoto's Thyroiditis

scholarly journals The Effect of Selenium on Hashimoto’s Thyroiditis; Systemic Review and Metaanalysis

2020 ◽  
Author(s):  
Ehsan Alijani
Keyword(s):  
Systematic Review ◽  
Hashimoto’S Thyroiditis ◽  
Meta Analysis ◽  
Active Form ◽  
The Body ◽  
Systemic Review ◽  
Hashimoto's Thyroiditis ◽  
P Value ◽  
Thyroid Status ◽  
Spss Software

AbstractBackgroundSelenium forms a significant component of seleno-proteins in the body. Seleno-methionine is integrated into proteins instead of methionine and acts as a storage pool. In proteins, the active form of Selenium is seleno-cysteine.in this review we aim to prevail the results of selenium effect on thyroid status in recent clinical trials. The systemic review aims to find out the correlation between supplementation of Selenium and anti-TPO antibodies and T4 levels in Hashimoto’s Thyroiditis. Selenium supplementation decreases the level of anti-TPO antibodies. The supplementation of Selenium increases the level of T4 levels.MethodsThe mean and standard deviation (SD) of all 8 studies was were calculated. One of the researches had all the information in figures, and only the levels of anti-TPO antibodies and FT4 were obtained. Heterogenicity was estimated using I2.ResultsThe p-value calculated for Anti-TPO by SPSS of the eight groups had a p-value of 0.142. The p-value calculated for T4 levels by SPSS of the five groups had a p-value of 0.239. The heterogenicity test was zero after the I2 test. The studies that were included in the systematic review were assessed by Prisma diagram and selected among the articles resulted from search keywords selenium and anti tpo and hashimotho thyroiditis on different data sources. All the participants were evaluated by sex, ages, duration of the study and the levels of anti tpo ab and thyroxin (t4) and then using SPSS software to deploy metanalysis in the systematic review.Conclusionin 6 of 8 studies it was a relation of selenium and thyroid status, whereas 2 studies were not. As We ran meta analysis on the data we realized that there is not significant desired effect from selenium on thyroid antibodies against previous metanalysis done by other researchers.

scholarly journals Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis

2021 ◽  
Vol 11 (7) ◽  
pp. 628
Author(s):  
Valeria Conti ◽  
Graziamaria Corbi ◽  
Carmine Sellitto ◽  
Francesco Sabbatino ◽  
Chiara Maci ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mortality Rate ◽  
Critically Ill Patients ◽  
Odds Ratio ◽  
Observational Studies ◽  
Meta Analysis ◽  
Regression Analyses ◽  
Log Odds ◽  
Meta Regression ◽  
Reduction Of Mortality

Data supporting the use of Tocilizumab (TCZ) in COVID-19 are contrasting and inconclusive. This meta-analysis aimed to assess TCZ effectiveness in reducing the mortality rate in COVID-19 patients. PubMed, Scopus, Embase, Cochrane, WILEY, and ClinicalTrials.gov were searched to evaluate observational studies and RCTs. The outcome was the mortality rate. Forty observational studies and seven RCTs, involving 9640 and 5556 subjects treated with Standard Therapy (ST) + TCZ or ST alone, respectively, were included. In patients treated with ST+TCZ, a higher survival (Log odds ratio = −0.41; 95% CI: −0.68 −0.14; p < 0.001) was found. Subgroups analyses were performed to better identify the possible interference of some parameters in modifying the efficacy of TCZ therapy on COVID-19 mortality. Separating observational from RCTs, no statistically significant (p = 0.70) TCZ-related reduction of mortality regarding RCTs was found, while a significant reduction (Log odds ratio = −0.52; 95% CI: −0.82 −0.22, p < 0.001) was achieved regarding the observational studies. Stratifying for the use of Invasive Mechanic Ventilation (IMV), a higher survival was found in patients treated with TCZ in the No-IMV and IMV groups (both p < 0.001), but not in the No-IMV/IMV group. Meta-regression analyses were also performed. The meta-analysis of observational studies reveals that TCZ is associated with reducing the mortality rate in both severe and critically ill patients. Although the largest RCT, RECOVERY, is in line with this result, the meta-analysis of RCTs failed to found any difference between ST + TCZ and ST. It is crucial to personalize the therapy considering the patients’ characteristics.

scholarly journals Association between HIV infection and hypertension: a global systematic review and meta-analysis of cross-sectional studies

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Katherine Davis ◽  
Pablo Perez-Guzman ◽  
Annika Hoyer ◽  
Ralph Brinks ◽  
Edward Gregg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Observational Studies ◽  
Meta Analysis ◽  
Hiv Status ◽  
Cross Sectional ◽  
Hypertension Risk ◽  
Meta Regression ◽  
Cross Sectional Studies ◽  
The Relationship ◽  
Hiv Negative

Abstract Background Improved access to effective antiretroviral therapy has meant that people living with HIV (PLHIV) are surviving to older ages. However, PLHIV may be ageing differently to HIV-negative individuals, with dissimilar burdens of non-communicable diseases, such as hypertension. While some observational studies have reported a higher risk of prevalent hypertension among PLHIV compared to HIV-negative individuals, others have found a reduced burden. To clarify the relationship between HIV and hypertension, we identified observational studies and pooled their results to assess whether there is a difference in hypertension risk by HIV status. Methods We performed a global systematic review and meta-analysis of published cross-sectional studies that examined hypertension risk by HIV status among adults aged > 15 (PROSPERO: CRD42019151359). We searched MEDLINE, EMBASE, Global Health and Cochrane CENTRAL to August 23, 2020, and checked reference lists of included articles. Our main outcome was the risk ratio for prevalent hypertension in PLHIV compared to HIV-negative individuals. Summary estimates were pooled with a random effects model and meta-regression explored whether any difference was associated with study-level factors. Results Of 21,527 identified studies, 59 were eligible (11,101,581 participants). Crude global hypertension risk was lower among PLHIV than HIV-negative individuals (risk ratio 0.90, 95% CI 0.85–0.96), although heterogeneity between studies was high (I2 = 97%, p < 0.0001). The relationship varied by continent, with risk higher among PLHIV in North America (1.12, 1.02–1.23) and lower among PLHIV in Africa (0.75, 0.68–0.83) and Asia (0.77, 0.63–0.95). Meta-regression revealed strong evidence of a difference in risk ratios when comparing North American and European studies to African ones (North America 1.45, 1.21–1.74; Europe 1.20, 1.03–1.40). Conclusions Our findings suggest that the relationship between HIV status and prevalent hypertension differs by region. The results highlight the need to tailor hypertension prevention and care to local contexts and underscore the importance of rapidly optimising integration of services for HIV and hypertension in the worst affected regions. The role of different risk factors for hypertension in driving context-specific trends remains unclear, so development of further cohorts of PLHIV and HIV-negative controls focused on this would also be valuable.

Sign in / Sign up

Export Citation Format

Share Document